Literature DB >> 3597737

The effect of dydrogesterone supplementation in an IVF programme.

J Belaisch-Allart, J Testart, N Fries, R G Forman, R Frydman.   

Abstract

Various treatments are given during the luteal phase by most IVF programmes, without any proof of their efficacy. We have performed a double-blind, randomized study with dydrogesterone (125 transfers) against placebo (133 transfers). The pregnancy rate was 21.6 versus 15.0% per transfer cycle with dydrogesterone or placebo, respectively. There was no significant difference between these figures, but taking into account the usual success rate in IVF programmes (15-20%) a difference of 5% would be significant only with two groups of 1500 subjects. This paper discusses the question of how we can come to a definite conclusion on the efficacy of hormonal supplementation during the luteal phase.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3597737     DOI: 10.1093/oxfordjournals.humrep.a136511

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

Review 1.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

2.  Assessment of the luteal phase in stimulated and substituted cycles.

Authors:  H M Fatemi
Journal:  Facts Views Vis Obgyn       Date:  2009

3.  Luteal Phase Support in assisted reproductive technology treatment: focus on Endometrin(R) (progesterone) vaginal insert.

Authors:  Jerome H Check
Journal:  Ther Clin Risk Manag       Date:  2009-06-04       Impact factor: 2.423

4.  Early-Pregnancy Dydrogesterone Supplementation Mimicking Luteal-Phase Support in ART Patients Did Not Provoke Major Reproductive Disorders in Pregnant Mice and Their Progeny.

Authors:  Laura Jeschke; Clarisa Guillermina Santamaria; Nicole Meyer; Ana Claudia Zenclussen; Julia Bartley; Anne Schumacher
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.